Number: GOG 250 Principal Investigator: Mutch, David
Title: A Randomized Phase III Evaluation of Docetaxel and Gemcitabine plus GCSF with Bevacizumab versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus
Phase: III Disease Site: Corpus Uteri
Participating Site(s):
Contact: 800-600-3606 or

Currently leiomyosarcoma may be treated with a combination of two chemotherapy drugs, which are gemcitabine and docetaxel. These two chemotherapy drugs have already shown to be effective in treating leiomyosarcoma. The purpose of the study is to compare treatment with gemcitabine plus docetaxel to treatment of gemcitabine plus docetaxel plus the addition of a third drug, called bevacizumab. In this study both groups of patients will receive the standard combination of gemcitabine plus docetaxel. However, in addition to the standard treatment with gemcitabine and docetaxel, half of the patients in the study will also receive the experimental drug bevacizumab, and the other half of the patients will receive standard gemcitabine and docetaxel plus a placebo (instead of the experimental drug bevacizumab).
More Information:
Internal Protocol Documents (requires Siteman administrative database password)